Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GLOBUS MEDICAL INCGMED · Entity 3496 | Director | September 15, 2026 | September 16, 2026 |
| Lyra Therapeutics, Inc.LYRA · Entity 46837 | Director | May 14, 2025 | May 16, 2025 |
| TransMedics Group, Inc.TMDX · Entity 4261 | Director | August 17, 2026 | August 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GLOBUS MEDICAL INC
Report date September 15, 2026 · Filed September 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-09-15 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-09-15 · Exercise / conversion · Acquired 15,000 · Balance 15,000 Row 2 · 2026-09-15 · Exercise / conversion · Acquired 15,000 · Balance 30,000 Row 3 · 2026-09-15 · Sale · Disposed 30,000 · Balance 0 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.33 to $74.96, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. |
| Stock Option (Right to Buy Class A Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $53.75 · Expires 2034-01-26 | Direct | 0 |
Reported balance
After 2026-09-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-09-15 · Exercise / conversion · Disposed 15,000 · Balance 0 F2: These options were granted on January 26, 2024 and are fully vested. |
| Stock Option (Right to Buy Class A Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $63.68 · Expires 2032-01-27 | Direct | 0 |
Reported balance
After 2026-09-15 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-09-15 · Exercise / conversion · Disposed 15,000 · Balance 0 F3: These options were granted on January 27, 2022 and are fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.33 to $74.96, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
F2: These options were granted on January 26, 2024 and are fully vested.
F3: These options were granted on January 27, 2022 and are fully vested.
Lyra Therapeutics, Inc.
Report date May 14, 2025 · Filed May 16, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 32,000 |
Reported balance
After 2025-05-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-14 · Grant · Acquired 32,000 · Balance 32,000 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest as to 100% on the earlier of (i) the day before the Issuer's next annual meeting, (ii) May 14, 2026 and (iii) upon a Change in Control as defined in the 2020 Incentive Award Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest as to 100% on the earlier of (i) the day before the Issuer's next annual meeting, (ii) May 14, 2026 and (iii) upon a Change in Control as defined in the 2020 Incentive Award Plan.
TransMedics Group, Inc.
Report date August 17, 2026 · Filed August 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy The Tobin 2024 Family Trust | 0 |
Reported balance
After 2026-08-17 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-08-17 · Gift · Disposed 18,000 · Balance 0 |
| Common StockSEC Table I · non-derivative | Direct | 6,981 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 6,981 |
| Common StockSEC Table I · non-derivative | IndirectBy the James R. Tobin 2012 Trust | 155,146 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 155,146 |
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Corindus Vascular Robotics, Inc.
Report date October 29, 2019 · Filed October 31, 2019
Section 16 reporting ended · disclosed 2019-10-31. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-10-29 transaction · row 1
1 source rowRow 1 · 2019-10-29 · Disposition to issuer · Disposed 106,112 · Balance 0 F1: On October 29, 2019, Siemens Medical Solutions USA, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Corpus Merger Inc., a Delaware corporation and wholly-owned subsidiary of Parent ("Merger Sub"), dated as of August 7, 2019 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). F2: These shares represent 85,375 shares of the Issuer's common stock and 20,737 restricted stock units ("RSUs"). F3: At the effective time of the Merger (the "Effective Time"), which occurred on October 29, 2019, (i) each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $4.28 in cash, without interest and less any applicable withholding taxes, and (ii) each outstanding RSU converted into the right to receive a cash payment equal to the product of (a) $4.28 and (b) the number of shares of the Issuer's common stock underlying the RSU as of the Effective Time, without interest and net of any applicable withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: On October 29, 2019, Siemens Medical Solutions USA, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Corpus Merger Inc., a Delaware corporation and wholly-owned subsidiary of Parent ("Merger Sub"), dated as of August 7, 2019 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger").
F2: These shares represent 85,375 shares of the Issuer's common stock and 20,737 restricted stock units ("RSUs").
F3: At the effective time of the Merger (the "Effective Time"), which occurred on October 29, 2019, (i) each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $4.28 in cash, without interest and less any applicable withholding taxes, and (ii) each outstanding RSU converted into the right to receive a cash payment equal to the product of (a) $4.28 and (b) the number of shares of the Issuer's common stock underlying the RSU as of the Effective Time, without interest and net of any applicable withholding taxes.
Oxford Immunotec Global PLC
Report date March 08, 2021 · Filed March 12, 2021
Section 16 reporting ended · disclosed 2021-03-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-03-08 transaction · row 1
1 source rowRow 1 · 2021-03-08 · Disposition to issuer · Disposed 4,081 · Balance 0 F1: Disposed pursuant to the acquisition by PerkinElmer (UK) Holdings Limited of the entire issued share capital of Oxford Immunotec Global PLC on March 8, 2021 by means of a scheme of arrangement under Part 26 of the Companies Act 2006 (the "Scheme"). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.65 · Expires 2026-06-28 | Direct | 0 |
Reported balance
After 2021-03-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-03-08 · Disposition to issuer · Disposed 7,457 · Balance 0 F3: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.46 · Expires 2027-06-06 | Direct | 0 |
Reported balance
After 2021-03-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-03-08 · Disposition to issuer · Disposed 7,457 · Balance 0 F3: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.49 · Expires 2028-06-19 | Direct | 0 |
Reported balance
After 2021-03-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-03-08 · Disposition to issuer · Disposed 7,457 · Balance 0 F3: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.44 · Expires 2029-06-18 | Direct | 0 |
Reported balance
After 2021-03-08 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-03-08 · Disposition to issuer · Disposed 7,457 · Balance 0 F3: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.02 · Expires 2024-12-01 | Direct | 0 |
Reported balance
After 2021-03-08 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-03-08 · Disposition to issuer · Disposed 14,914 · Balance 0 F3: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.02 · Expires 2024-12-01 | Direct | 0 |
Reported balance
After 2021-03-08 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-03-08 · Disposition to issuer · Disposed 7,457 · Balance 0 F3: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.17 · Expires 2025-06-09 | Direct | 0 |
Reported balance
After 2021-03-08 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-03-08 · Disposition to issuer · Disposed 7,457 · Balance 0 F3: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.96 · Expires 2030-06-24 | Direct | 0 |
Reported balance
After 2021-03-08 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2021-03-08 · Disposition to issuer · Disposed 9,494 · Balance 0 F3: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price. F2: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed pursuant to the acquisition by PerkinElmer (UK) Holdings Limited of the entire issued share capital of Oxford Immunotec Global PLC on March 8, 2021 by means of a scheme of arrangement under Part 26 of the Companies Act 2006 (the "Scheme").
F2: In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price.
F3: Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 26, 2019 Filed Feb 28, 2019 22:27 UTC | GLOBUS MEDICAL INC GMED · Entity 3496 | Exercise / conversionStock Option (Right to Buy Class A Common Stock) · Derivative | 8,900 | $0.00 Strike: $24.75 | $0.00 |
DisclosureSEC source: 0001209191-19-014613 · doc4.xml · derivative · entry 9 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,100 Underlying: Class A Common Stock · 8,900 shares Expires 2025-08-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options were granted on August 28, 2015, and vested over a three-year period with one-twelfth (1/12) of the options granted vesting on December 31, 2015, and the balance of the options granted vesting ratably on a quarterly basis over the following 11 quarters. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 22:27 UTC | GLOBUS MEDICAL INC GMED · Entity 3496 | SaleClass A Common Stock | 400 | $47.91 | $19,164.00 |
DisclosureSEC source: 0001209191-19-014613 · doc4.xml · nonDerivative · entry 3 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 22:27 UTC | GLOBUS MEDICAL INC GMED · Entity 3496 | SaleClass A Common Stock | 8,500 | $47.06 | $400,010.00 |
DisclosureSEC source: 0001209191-19-014613 · doc4.xml · nonDerivative · entry 2 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.83 to $47.56, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 22:27 UTC | GLOBUS MEDICAL INC GMED · Entity 3496 | Exercise / conversionClass A Common Stock | 8,900 | $24.75 | $220,275.00 |
DisclosureSEC source: 0001209191-19-014613 · doc4.xml · nonDerivative · entry 1 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 22, 2019 Filed Feb 11, 2019 21:47 UTC | GLOBUS MEDICAL INC GMED · Entity 3496 | GrantStock Option (Right to Buy Class A Common Stock) · Derivative | 25,000 | $0.00 Strike: $43.58 | $0.00 |
DisclosureSEC source: 0001209191-19-008989 · doc4.xml · derivative · entry 1 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Class A Common Stock · 25,000 shares Expires 2029-01-22 F1 · derivative.exercise_date: These options were granted on January 22, 2019, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on January 1, 2020, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months. Read SEC document |
| January 08, 2019 Filed Jan 10, 2019 22:36 UTC | Corindus Vascular Robotics, Inc. CVRS · Entity 154132 | GrantCommon Stock | 4,464 | $1.12 | $4,999.68 |
DisclosureSEC source: 0001387131-19-000163 · ownership.xml · nonDerivative · entry 1 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,482 F1 · shares: The common stock was issued to the reporting person pursuant to the Corindus Vascular Robotics, Inc. ("Corindus") Director Compensation Policy in lieu of the reporting person's quarterly retainer of $5,000. F2 · balance_after: Includes 53,326 shares of common stock related to restricted stock units ("RSUs") granted as part of the director's 2018 annual equity award. The RSUs provide for vesting in quarterly installments on August 31, 2018, November 30, 2018, February 28, 2019 and May 31, 2019, subject to the reporting person's continuous service with Corindus through each such vesting date. F3 · balance_after: Includes 8,219 shares of common stock related to RSUs granted as part of the director's 2017 annual equity award with vesting beginning as of March 13, 2018, the date of the reporting person's appointment as a director. The RSUs vest in four quarterly installments on June 13, 2018, September 13, 2018, December 13, 2018 and March 13, 2019, subject to the reporting person's continuous service with Corindus through each such vesting date. Read SEC document |
| October 05, 2018 Filed Oct 9, 2018 23:01 UTC | Corindus Vascular Robotics, Inc. CVRS · Entity 154132 | GrantCommon Stock | 3,200 | $1.25 | $4,000.00 |
DisclosureSEC source: 0001387131-18-005359 · tobin-form4_100518.xml · nonDerivative · entry 1 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,018 F1 · shares: The common stock was issued to the reporting person pursuant to the Corindus Vascular Robotics, Inc. ("Corindus") Director Compensation Policy in lieu of the reporting person's quarterly retainer of $4,000. F2 · balance_after: Includes 53,326 shares of common stock related to restricted stock units ("RSUs") granted as part of the director's 2018 annual equity award. The RSUs provide for vesting in quarterly installments on August 31, 2018, November 30, 2018, February 28, 2019 and May 31, 2019, subject to the reporting person's continuous service with Corindus through each such vesting date. F3 · balance_after: Includes 8,219 shares of common stock related to RSUs granted as part of the director's 2017 annual equity award with vesting beginning as of March 13, 2018, the date of the reporting person's appointment as a director. The RSUs vest in four quarterly installments on June 13, 2018, September 13, 2018, December 13, 2018 and March 13, 2019, subject to the reporting person's continuous service with Corindus through each such vesting date. Read SEC document |
| July 09, 2018 Filed Jul 12, 2018 00:51 UTC | Corindus Vascular Robotics, Inc. CVRS · Entity 154132 | GrantCommon Stock | 4,273 | $1.17 | $4,999.41 |
DisclosureSEC source: 0001387131-18-003105 · tobin-form4_070918.xml · nonDerivative · entry 1 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,818 F1 · shares: The common stock was issued to the reporting person pursuant to the Corindus Vascular Robotics, Inc. ("Corindus") Director Compensation Policy in lieu of the reporting person's quarterly retainer of $5,000. F2 · balance_after: Includes 53,326 shares of common stock related to restricted stock units ("RSUs") granted as part of the director's 2018 annual equity award. The RSUs provide for vesting in quarterly installments on August 31, 2018, November 30, 2018, February 28, 2019 and May 31, 2019, subject to the reporting person's continuous service with Corindus through each such vesting date. F3 · balance_after: Includes 8,219 shares of common stock related to RSUs granted as part of the director's 2017 annual equity award with vesting beginning as of March 13, 2018, the date of the reporting person's appointment as a director. The RSUs vest in four quarterly installments on June 13, 2018, September 13, 2018, December 13, 2018 and March 13, 2019, subject to the reporting person's continuous service with Corindus through each such vesting date. Read SEC document |
| June 19, 2018 Filed Jun 21, 2018 20:31 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | GrantSHARE OPTION (RIGHT TO BUY) · Derivative | 7,457 | $0.00 Strike: $14.49 | $0.00 |
DisclosureSEC source: 0001437749-18-012238 · rdgdoc.xml · derivative · entry 1 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,457 Underlying: ORDINARY SHARES · 7,457 shares Expires 2028-06-19 F1 · derivative.exercise_date: The option will vest and become exercisable as to 100% of the underlying shares on the date of the first annual meeting of the issuer's shareholders held after the date of grant. Read SEC document |
| May 31, 2018 Filed Jun 4, 2018 22:02 UTC | Corindus Vascular Robotics, Inc. CVRS · Entity 154132 | GrantCommon Stock | 53,326 | $0.75 | $39,999.83 |
DisclosureSEC source: 0001387131-18-002523 · tobin-form4_053118.xml · nonDerivative · entry 1 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,545 F1 · shares: The common stock represents shares issuable upon vesting of restricted stock units (RSUs) granted as part of the director's 2018 annual equity award. The RSUs provide for vesting in quarterly installments on August 31, 2018, November 30, 2018, February 28, 2019 and May 31, 2019, subject to the reporting person's continuous service with Corindus Vascular Robotics, Inc. (Corindus) through each such vesting date. F2 · balance_after: Includes 8,219 shares of common stock related to RSUs granted as part of the director's 2017 annual equity award with vesting beginning as of March 13, 2018, the date of the reporting person's appointment as a director. The RSUs vest in four equal quarterly installments on June 13, 2018, September 13, 2018, December 13, 2018 and March 13, 2019, subject to the reporting person's continuous service with Corindus through each such vesting date. Read SEC document |
| March 13, 2018 Filed Mar 15, 2018 21:43 UTC | Corindus Vascular Robotics, Inc. CVRS · Entity 154132 | GrantCommon Stock | 8,219 | $0.00 | $0.00 |
DisclosureSEC source: 0001387131-18-001084 · cvrs-form4_tobin031318.xml · nonDerivative · entry 1 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,219 F1 · shares: The common stock represents shares issuable upon vesting of restricted stock units granted as part of the director's annual equity award with vesting beginning as of March 13, 2018, the date of the reporting person's appointment as a director. The restricted stock units vest in four equal quarterly installments on June 13, 2018, September 13, 2018, December 13, 2018 and March 13, 2019, subject to the reporting person's continuous service with Corindus Vascular Robotics, Inc. through each such vesting date. F1 · balance_after: The common stock represents shares issuable upon vesting of restricted stock units granted as part of the director's annual equity award with vesting beginning as of March 13, 2018, the date of the reporting person's appointment as a director. The restricted stock units vest in four equal quarterly installments on June 13, 2018, September 13, 2018, December 13, 2018 and March 13, 2019, subject to the reporting person's continuous service with Corindus Vascular Robotics, Inc. through each such vesting date. Read SEC document |
| January 22, 2018 Filed Jan 24, 2018 21:22 UTC | GLOBUS MEDICAL INC GMED · Entity 3496 | GrantStock Option (Right to Buy Class A Common Stock) · Derivative | 25,000 | $0.00 Strike: $43.77 | $0.00 |
DisclosureSEC source: 0001209191-18-005112 · doc4.xml · derivative · entry 1 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Class A Common Stock · 25,000 shares Expires 2028-01-22 F1 · derivative.exercise_date: These options vest over a three-year period with one-twelfth (1/12) of the options granted vesting on March 31, 2018, and the balance of the options granted vesting ratably on a quarterly basis over the following 11 quarters. Read SEC document |
| June 06, 2017 Filed Jun 8, 2017 20:32 UTC | Oxford Immunotec Global PLC OXFD · Entity 141404 | GrantSHARE OPTION (RIGHT TO BUY) · Derivative | 7,457 | $0.00 Strike: $14.46 | $0.00 |
DisclosureSEC source: 0001437749-17-010970 · rdgdoc.xml · derivative · entry 1 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,457 Underlying: ORDINARY SHARES · 7,457 shares Expires 2027-06-06 F1 · derivative.exercise_date: The option will vest and become exercisable as to 100% of the underlying shares on the date of the first annual meeting of the issuer's shareholders held after the date of grant. Read SEC document |
| January 30, 2017 Filed Feb 1, 2017 21:12 UTC | GLOBUS MEDICAL INC GMED · Entity 3496 | GrantStock Option (Right to Buy Class A Common Stock) · Derivative | 25,000 | $0.00 Strike: $26.27 | $0.00 |
DisclosureSEC source: 0001209191-17-006667 · doc4.xml · derivative · entry 1 TOBIN JAMES R · CIK 0001190128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Class A Common Stock · 25,000 shares Expires 2027-01-30 F1 · derivative.exercise_date: These options vest over a three-year period with one-twelfth (1/12) of the options granted vesting on March 31, 2017, and the balance of the options granted vesting ratably on a quarterly basis over the following 11 quarters. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.